# Pizarra — PT-pseudo_4b950525e6a8 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4b950525e6a8
Task: 1

Encounter: Urology - outpatient on 01 Mar 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 19.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.37 ng/mL²
  - PSA velocity: 2.0 ng/mL/yr
  - Prior PSA: 18.4 ng/mL
  - Prostate volume: 51.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.88825184 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Benign prostatic hyperplasia
  - Current medication: amlodipine, valsartan, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 19 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 51 mL. csPCa 0.89.

Vitals: weight 80 kg, height 175 cm, BMI 26.1, BP 134/81 mmHg, HR 80 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2022).

Chief complaint: Current PSA reading of 19.0 ng/mL alongside a previous prostate cancer diagnosis necessitates clinical review.

History: A 65-year-old retired shopkeeper, widowed, occupies a ground-floor flat shared with his partner, who helps manage daily routines. Alcohol consumption is entirely avoided, and he walks for twenty minutes daily to stay active. Lower urinary tract complaints are moderately bothersome, scoring 22 out of 35 on the IPSS, currently controlled with tamsulosin while amlodipine and valsartan address his hypertension. He carries a benign prostatic hyperplasia diagnosis. Smoking ceased in 2022 after accumulating 30 pack-years. His adult daughter serves as his main contact; she recently visited for a routine dermatology check on stable actinic keratosis. He reports no unexplained weight loss, bone discomfort, or haematuria.

Physical examination: DRE — texture: smooth and firm; symmetry: uniform; nodularity: absent. The prostate presents as symmetrically enlarged without palpable irregularities. Systemic review shows normal heart and lung sounds, with no hepatosplenomegaly or peripheral lymphadenopathy. Cardiovascular and respiratory systems remain unremarkable. Blood pressure registers at 134/81 mmHg, heart rate at 80 bpm, and vital parameters are stable.

Patient info: retired shopkeeper; Widowed; Lives in ground-floor apartment with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 22/35 (severe LUTS).

Recent other appointments: Dermatology — actinic keratosis check.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.57 +/- 0.19   (95% CI 0.18-0.91)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 6.8 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=19.0, age=65.0, psad=0.37, dre_ord=0.0, vol=51.0, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the patient's PSA velocity (2.0 ng/mL/yr) against the high csPCa predicted probability (0.88825184), which suggests a more aggressive trajectory than the static values alone imply. It also missed the context provided by the mpMRI report (PI-RADS 5) in conjunction with the high PSA, which is a critical combination. Finally, it did not see the specific details from the retrieved documents, such as the full PSA history trend or the laboratory panel, which might contextualize the current PSA of 19.0 ng/mL.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'BIOPSY' with a wide interval (0.57 +/- 0.19), indicating high uncertainty. The high csPCa probability (0.888) and PI-RADS 5 are strong indicators for biopsy, but the prior cannot account for the fact that the patient has a prior positive biopsy status, which fundamentally changes the question from "does he have cancer" to "is the cancer recurrent/new/different." The prior cannot weigh the clinical significance of the PI-RADS 5 against the prior positive biopsy result.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details specific suspicious lesions or features, it would refine the PI-RADS 5 assessment and guide the need for biopsy.
  <document> PSA history (trend) -> If the trend shows a rapid rise, it would increase the urgency for intervention regardless of the prior biopsy.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the prior diagnosis or any follow-up plans that influence the current decision.
  <document> laboratory results (full panel) -> This panel might reveal other markers (e.g., PSA density, other inflammatory markers) that modify the risk assessment.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units and dates. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_4b950525e6a8", "radiology_report": "Radiology Division | Antoni van Leeuwenhoek | 15 February 2025\nStudy: Multiparametric MRI of the Prostate\nReason for scan: Follow-up for raised PSA (19.0 ng/mL) and historically positive biopsy. Earlier studies flagged a PI-RADS 5 abnormality.\n\nOBSERVATIONS:\nProstatic volume registers at 51.0 mL. T2 sequences show a discrete hypointense focus in the left peripheral zone spanning base to mid gland, spanning roughly 18 mm. DWI displays intense restriction, mirrored by dark signal on the ADC map. Post-contrast phases capture prompt, localized enhancement against the background parenchyma. Margins remain intact; seminal vesicles are uninvolved. Lymph nodes appear normal, and bone windows are clear.\n\nCONCLUSION:\nPI-RADS 5 lesion in the left peripheral zone (base/mid), measuring ~18 mm.\nProstate volume 51.0 mL; PSA density 0.37 ng/mL/mL.\ncsPCa predicted probability 0.88825184."}

  **psa_trend**
  {"case_id": "PT-pseudo_4b950525e6a8", "psa_trend": [{"date": "Jul 2023", "val": 2.1}, {"date": "May 2024", "val": 6.3}, {"date": "Mar 2025", "val": 19.0}]}

  **lab_results**
  {"case_id": "PT-pseudo_4b950525e6a8", "laboratory_results": [{"name": "PSA", "val": "19.0 ng/mL", "date": "10 Feb 2025", "flag": "H"}, {"name": "Free PSA", "val": "2.18 ng/mL", "date": "10 Feb 2025", "flag": ""}, {"name": "%Free PSA", "val": "11%", "date": "10 Feb 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "14.3 g/dL", "date": "10 Feb 2025", "flag": ""}, {"name": "WBC", "val": "6.3 x10^9/L", "date": "10 Feb 2025", "flag": ""}, {"name": "Platelets", "val": "301 x10^9/L", "date": "10 Feb 2025", "flag": ""}, {"name": "Creatinine", "val": "100 umol/L", "date": "10 Feb 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "10 Feb 2025", "flag": ""}, {"name": "Testosterone", "val": "15.1 nmol/L", "date": "10 Feb 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "98 U/L", "date": "10 Feb 2025", "flag": ""}, {"name": "LDH", "val": "202 U/L", "date": "10 Feb 2025", "flag": ""}, {"name": "HbA1c", "val": "6.5 %", "date": "10 Feb 2025", "flag": ""}]}

  **previous_notes**
  {"case_id": "PT-pseudo_4b950525e6a8", "previous_notes": [{"date": "04 Jul 2024", "author": "Dr. F. de Boer (GP)", "text": "Patient presented with persistently rising PSA values, climbing from 15.0 ng/mL in July 2023 to 18.4 ng/mL by May 2024. After weighing procedural risks against diagnostic benefits, a transrectal biopsy was conducted on 04 July 2024, yielding a diagnosis of Gleason 4+4 carcinoma. Pathology results were relayed to the patient."}]}

NOT RETRIEVED
  get_family_history: Not called because the retrieval of other documents provided sufficient context regarding the clinical picture and prior workup.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion in the left peripheral zone (base/mid), measuring ~18 mm.
  PSA velocity of 2.0 ng/mL/yr, indicating a significant rise since the last follow-up.
  csPCa predicted probability of 0.88825184.
  Prior positive biopsy result (Gleason 4+4 carcinoma).

  AGAINST sampling this patient now:
  Prior positive biopsy result (Gleason 4+4 carcinoma).

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-risk MRI finding (PI-RADS 5) and the concerning PSA velocity, which suggests progression or recurrence, despite the prior positive biopsy. This contradicts the inherent caution suggested by the prior positive biopsy result.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly points toward sampling due to the high-risk MRI finding (PI-RADS 5) and the concerning PSA velocity of 2.0 ng/mL/yr, which suggests progression or recurrence. This finding overrides the caution suggested by the prior positive biopsy result (bx), as the PI-RADS 5 lesion and rising PSA are critical factors. The statistical prior suggested biopsy, and the retrieved evidence confirms the need for further tissue sampling.

Variables that carried weight: bx=decisive, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
